Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis

In the current study, a novel niosome based formulation of diallyl disulfide (DADS) was evaluated for its potential to treat disseminated candidiasis in mouse model. Among various non-ionic surfactants tested, niosome formulation prepared using Span 80 was found to be most efficient in the entrapment of DADS. The DADS loaded niosomes had size dimensions in the range of 140 ± 30 nm with zeta potential of − 30.67 ± 4.5. Liver/kidney function tests as well as histopathologic studies suggested that noisome-based DADS formulations are safe at the dose investigated. When administered to Candida albicans infected animals, the DADS bearing niosomal formulation cleared the fungal burden and increased their survival much efficiently than its free form.From the Clinical EditorIn this study, a novel niosomal formulation of the antifungal DADS was utilized in a murine candidiasis model, resulting in more efficient fungal clearance compared to the free formulation.

Graphical AbstractOn incorporation of DADS in non-ionic surfactant based niosomes, it reduces fungal burden and increases survival in infected animals significantly compared with free form of DADS.Figure optionsDownload high-quality image (153 K)Download as PowerPoint slide